Background/Aims: NLRP3 inflammasome activation has been reported to be an early mechanism responsible for glomerular inflammation and injury in obese mice. However, the precise mechanism of obesity-induced NLRP3 inflammasome activation remains unknown. The present study explored whether adipokine visfatin mediates obesity-induced NLRP3 inflammasome activation and consequent podocyte injury. Methods: Inflammasome formation and immunofluorescence expressions were quantified by confocal microscopy. Caspase-activity, IL-1β production and VEGF concentrations were measured by ELISA. Results: Confocal microscopic analysis showed that visfatin treatment increased the colocalization of Nlrp3 with Asc or Nlrp3 with caspase-1 in podocytes indicating the formation of NLRP3 inflammasomes. This visfatin-induced NLRP3 inflammasome formation was abolished by pretreatment of podocytes with Asc siRNA. Correspondingly, visfatin treatment significantly increased the caspase-1 activity and IL-1β production in podocytes, which was significantly attenuated by Asc siRNA transfection. Further RT-PCR and confocal microscopic analysis demonstrated that visfatin treatment significantly decreased the podocin expression (podocyte damage). Podocytes pretreatment with Asc siRNA or caspase-1 inhibitor, WEHD attenuated this visfatin-induced podocin reduction. Furthermore, Asc siRNA transfection was found to preserve podocyte morphology by maintaining the distinct arrangement of F-actin fibers normally lost in response to visfatin. It also prevented podocyte dysfunction by restoring visfatin-induced suppression of VEGF production and secretion. Conclusion: Visfatin induces NLRP3 inflammasome activation in podocytes and thereby resulting in podocyte injury.
starved for 12 h and then transfected with ASC siRNA or scrambled siRNA using siLentFect Lipid Reagent (Bio-Rad, Hercules, CA, USA). After 18 h of incubation at 37 °C, the medium was changed and visfatin (2 µg/ ml) added into the medium for indicated time spans in different protocols.
Real-time reverse transcription polymerase chain reaction (RT-PCR)
Total RNA from cultured podocytes or isolated mouse glomeruli was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA. USA) according to the protocol described by the manufacturer. The primers used in this study were synthesized by Operon (Huntsville, AL, USA) and the sequences were: for podocin sense GTGGAAGCTGAGGCACAAAGAC, antisense CAGCGACTGAAGA GTGTGCAAG; and for β-actin sense TCGCTGCGCTGGTCGTC antisense GGCCTCGTCACCCACATAGGA.
Indirect immuno-fluorescent staining and confocal microscopy
For colocalization of inflammasome molecules in podocytes, cultured cells were fixed in 4% PFA for 15 minutes. After being rinsed with phosphate-buffer saline (PBS), the cells were incubated overnight at 4°C with goat anti-NLRP3 (1:200, Abcam, Cambridge, MA, USA) and rabbit anti-ASC (1:50, Enzo, Plymouth Meeting, PA ), or goat anti-NLRP3 (1:200) and anti-caspase-1 (1:100, Abcam, Cambridge, MA, USA) or rabbit anti-podocin or mouse anti-desmin antibodies. After washing, these slides probed with primary antibodies were incubated with Alexa-488-or Alexa-555-labeled secondary antibodies for 1 h at room temperature (Invitrogen, catalog # A11055 or A-31572). After being mounted with DAPI-containing mounting solution, the slides were subjected to examinations using a confocal laser scanning microscope (Fluoview FV1000, Olympus, Japan), with photos being taken and the colocalization of NLRP3 with ASC or caspase-1 analyzed by the Image Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD, USA). The data was expressed as Pearson correlation coefficient (PCC) as we described previously [13] .
Direct fluorescent staining of F-actin
To determine the role of NLRP3 inflammasome activation in visfatin-induced cytoskeleton changes, podocytes were cultured in 8-well chambers. After pretreatment with vehicle or transfected with ASC siRNA or scrambled siRNA, the cells were treated with visfatin (2 ug/ml) for 16 h. After washing with PBS, the cells were fixed in 4% paraformaldehyde for 15 min at room temperature, permeabilized with 0.1% Triton X-100, and blocked with 3% bovine serum albumin. F-actin was stained with rhodamine-phalloidin (Invitrogen, Carlsbad, CA, USA) for 15 min at room temperature. After mounting, the slides were examined by a confocal laser scanning microscope.
Assay of the permeability through podocytes monolayer
Podocytes were cultured in 24-well transwell plates and treated as indicated for 24 hr. The transwell inserts were moved into non-used wells with 200 μl fresh media. 100 μl Fluorescein isothiocyanate (FITC)-dextran (10 KDa, Invitrogen) solution was added into each insert and the plate was incubated at 37°C for 2 hours to allow fluorescein molecules flow through the endothelial cell monolayer. The inserts were then removed and fluorescent intensity in each well was determined at excitation/emission of 485/530 nm using a fluorescent microplate reader (FL × 800, BIO-TEK Instruments). The arbitrary fluorescence intensity was used to calculate the relative permeability [14] .
ELISA for VEGF-A secretion by podocytes
Podocytes were incubated with different stimulations like visfatin (2 μg/ml) with or without Asc siRNA transfection or WEHD treatment for 12 h. The supernatant was collected for ELISA to measure VEGF-A using a commercially available kit (R&D Systems, Minneapolis, MN, USA).
Caspase-1 activity, IL-1β production
Caspase-1 activity in podocytes (30 µg/30µl) was measured by a commercially available colorimetric assay kit (Biovision, Mountain View, CA). IL-1β production in podocytes supernatant was measured by a commercially available ELISA kit (R&D System, Minneapolis, MN), according to the manufacturer's instructions [15, 16] . .-production, proteins from cultured podocytes were extracted using sucrose buffer and resuspended with modified Kreb's-Hepes buffer containing deferoximine (100 mM, Sigma) and diethyldithiocarbamate (5 mM, Sigma). The Nox-dependent O 2 .-production was examined by addition of 1mM NADPH as a substrate in 50 mg protein and incubated for 15 min at 37 0 C in the presence or absence of SOD (200 U/ml), and then supplied with 1mM O 2 .-specific spin trap 1-hydroxy-3-methoxycarbonyl-2, 2,5, 5-tetramethylpyrrolidine (CMH, Noxygen, Elzach, Germany). The mixture was loaded in glass capillaries and immediately analyzed for O 2 .-production kinetically for 10 min in a Miniscope MS200 electromagnetic spin resonance (ESR) spectrometer (Magnettech Ltd, Berlin, Germany). The ESR settings were as follows: biofield, 3350; field sweep, 60 G; microwave frequency, 9.78 GHz; microwave power, 20mW; modulation amplitude, 3 G; 4, 096 points of resolution; receiver gain, 50 for cells. The results were expressed as the fold changes of control.
Statistical Analysis
Data are provided as arithmetic means ± SEM; n represents the number of independent experiments. All data were tested for significance using ANOVA or paired and unpaired Student's t-test as applicable. Only results with p<0.05 were considered statistically significant.
Results

Inhibition of Asc attenuated visfatin-
induced NLRP3 inflammasome formation We tested whether visfatin-induced NLRP3 inflammasome formation and activation in podocytes. Using confocal microscopy, we demonstrated that visfatin (2 µg/ml, 16 hrs) treatment increased colocalization of inflammasome molecules (Nlrp3 with Asc), as shown by yellow spots in podocytes compared to control cells (Fig. 1A) . However, prior treatment with Asc siRNA attenuated the visfatininduced NLRP3 inflammasome formation in podocytes ( Fig. 1A and 1B) . The summarized data of quantitative co-localization of Nlrp3 with Asc or Nlrp3 with caspase-1 in podocytes were shown in Fig. 1B .
Inhibition of Asc abrogated visfatininduced increases in caspase-1 activity and IL-1β secretion
First demonstrated by Srinivasula et al. it is known that the formation of NLRP3 inflammasomes results in downstream caspase-1 activation and subsequent IL-1β maturation [17] . These effects reflect the functionality of the formed inflammasomes and thus were used to determine the effect of Asc inhibition on visfatin-induced inflammasome activation in the current study. Visfatin significantly increased caspase-1 activity and Il-1β production in podocytes compared to control cells, suggesting activation of NLRP3 inflammasomes ( Fig. 2A and 2B ). Prior treatment with Asc siRNA transfection significantly attenuated visfatin-induced caspase-1 activity and IL-1β production.
Asc inhibition protects the podocytes from visfatin-induced damage
To assess the extent of podocyte damage, the protein expression of slit diaphragm molecules like podocin and desmin was monitored. Podocin, a podocytespecific marker, decreases in expression during injury, while podocyte damage marker desmin increases during injury. I m m u n o f l u o r e s c e n c e analysis demonstrated that visfatin-treated podocytes displayed a dramatic decrease of podocin staining and increase in desmin staining, signifying podocyte damage (Fig. 3A) . However, Asc inhibition or WEHD prior treatment resulted in the protection of these podocyte damages as shown by normalized podocin and desmin protein expression to control levels Fig. 3A and 3B) . Moreover, the actin cytoskeleton organization with fibroblast-like stress extending into the foot processes was analyzed because such stress fibers in cultured podocytes correspond to the filamentous actin in podocyte foot processes in vivo, thus representing differentiation of podocytes. Visfatin-induced a dramatic disarrangement of F-actin, which was substantially blocked by prior treatment of Asc siRNA transfection (Fig.  4A) . Additionally, VEGF secretion is considered as an indicator of podocyte functionality because glomerular VEGF is primarily produced in podocytes. It was found that visfatin treated podocytes displayed significantly impaired secretion of VEGF, which was restored by prior treatment of these cells with Asc siRNA (Fig. 4B) . Taken together these data suggesting that visfatin-induced NLRP3 inflammasome activation contributes to podocyte injury.
Visfatin-Induced O 2 production in podocytes
Visfatin treatment significantly increased O 2 .-production compared with control cells (Fig.  5A) . However, prior treatment with reactive oxygen species scavenger, Tempol (0.1 mmol/L) for 30 minutes significantly attenuated the visfatin-induced O 2 .-production. In contrast, caspase-1 inhibitor, WEHD did not alter O 2 .-production induced by visfatin. These data suggest that visfatininduced activation of the NLRP3 inflammasomes might be through the NADPH oxidase dependent ROS production. Further, we examined whether the visfatin-induced redox signaling pathway is involved in visfatin-induced NLRP3 inflammasome activation in podocytes. We determined IL-1β production in podocytes with or without prior treatment of Tempol and WEHD. Visfatin treatment significantly increased IL-1β production compared with control cells (Fig. 5B) . However, prior treatment with Tempol and caspase-1 inhibitor, WEHD, significantly attenuated visfatin-induced IL-1β production.
Asc inhibition blocked visfatin-enhanced cell permeability in podocytes
Next, we determined the functional significance of NLRP3 inflammasome activation and examined its influence on visfatin-induced changes in barrier function in podocyte monolayers. As shown in Fig. 6 , dextran flux significantly increased in podocytes treated with visfatin. This visfatin- 
Discussion
The present study was designed to explore whether visfatin-induced NLRP3 inflammasome activation and contributes to the podocyte injury. We first confirmed that visfatin-induced the NLRP3 inflammasome formation and activation in podocytes. However, such inflammasome activation was attenuated in podocytes prior treatment with Asc siRNA transfection. In addition, inhibition of Asc gene or caspase-1 prevented the visfatin-induced podocyte injury and podocyte permeability. These findings for the first time demonstrate the critical role of Nlrp3 inflammasomes activation and subsequent podocyte injury or damage in response to visfatin during obesity.
The inflammasome is a newly identified intracellular machinery of inflammation [18] . Among different kinds of inflammasomes, the Nlrp3 inflammasome is the most fully characterized one in a variety of mammalian cells with high abundance in podocytes of glomeruli [16, 19, 20] . The inflammasome is a proteolytic complex composed of the Nodlike receptor protein 3 (also known as Nlrp3), the adaptor protein apoptosis-associated speck-like protein (Asc), and caspase-1 [21] , which is vital for the production of mature IL-1β in response to a variety of agonists or stimuli. It has been reported that IL-1β is an important cytokine with a broad range of biological activities [22, 23] involved in kidney injury or repair [16, 24, 25] and that in glomeruli it is mainly produced by podocytes [26, 27] . The active mature interleukin-1β (IL-1 β) is formed by cleavage of the inactive pro IL-1β precursor by caspase-1, which is activated in a large multiprotein complex, namely, the inflammasome [22, [28] [29] [30] [31] [32] [33] [34] . However, little is known about NLRP3 inflammasome contribution to the initiation or development of podocyte dysfunction or damage. Nlrp3 inflammasome has been implicated in the pathogenesis of various metabolic diseases, including obesity, diabetes, gout, silicosis, and acetaminophen-induced liver toxicity [21, 23, [35] [36] [37] [38] [39] [40] , acute ischemia/reperfusion-induced kidney injury [25] , unilateral ureteral obstruction [19, 20] , renal biopsies from patients with non-diabetic kidney disease [20] and obesity-induced glomerular injury [2] . The Nlrp3 inflammasome has been reported to be activated by bacterial toxins [18] , ATP, monosodium urate crystals [35] , β-amyloid [41] , muramyldipeptide [42] , cholesterol crystals [43] and other stimuli [23] . Moreover, recent studies demonstrated that visfatin has been contributor to endothelial dysfunction through the NLRP3 inflammasome activation in endothelial cells [12] . However, it remains unknown whether visfatin induces NLRP3 inflammasomes activation in podocytes and contributes to podocyte injury or dysfunction and consequent glomerular injury. In the present study, using confocal microscopy, we first confirmed that visfatin-induced the formation and activation of the NLRP3 inflammasome complex in podocytes, as shown by colocalization of NLRP3 with ASC or NLRP3 with caspase-1 and by biochemical analysis of caspase-1 activity and production of IL-1β. However, such inflammasome activation were abolished in podocytes with prior treatment with Asc siRNA or caspase-1 inhibitor, WEHD ( Fig. 1 and 2 ). These results clearly suggest that visfatin-induced NLRP3 inflammasome activation in podocytes, which may contribute to the development of podocyte injury or dysfunction. To our knowledge, the results from the present study provide the first experimental evidence demonstrated that visfatin-induced NLRP3 inflammasome activation in podocytes.
Next we tested a hypothesis that visfatin induces podocyte injury or dysfunction through the activation of Nlrp3 inflammasomes. Podocytes, the epithelial cells lining the outermost layer of the glomeruli, are essential for proper filtration, and injury to podocytes is indicative of impaired glomerular filtration, in time leading to glomerular sclerosis [44] [45] [46] . Foot process effacement, considered as the hallmark sign of podocyte injury, is usually accompanied by the destruction of the actin cytoskeleton, increased expression of slit diaphragm molecule and podocyte injury factor desmin, and reduction of the slit diaphragm molecule podocin, which is important for cell polarity and survival. The present study showed that stimulation of podocytes with visfatin decreased the podocin expression and increased the desmin expression. However, inhibition of inflammasome with WEHD or Asc siRNA was able to preserve the morphological structure of podocytes by keeping the distinct arrangement of the F-actin fibers intact and was functionally able to maintain podocin expression and prevent desmin expression increase.
To further explore the mechanism of visfatin-induced Nlrp3 inflammasome activation in podocytes, we determined the NADPH oxidase derived O 2 .-production in podocytes with or without stimulation of visfatin. It is well documented that several mechanisms underlying inflammasome activation have been reported, including lysosome rupture, ion channel gating, and reactive oxygen species (ROS) activation [15, 46] . Activation of the NLRP3 inflammasome by increased ROS, the most widely accepted and considered to be the most plausible mechanism, suggests that this inflammasome is a general sensor for changes in cellular oxidative stress. Indeed, the present study showed that visfatin significantly increased the NADPH oxidase-dependent O 2 .-production in podocytes compared to control cells. However, WEHD treatment could not prevent the visfatin-induced increase in superoxide. This suggests that NADPH oxidase activation by visfatin and subsequent production of superoxide are upstream of inflammasome activation, given that inhibition of the inflammasome did not affect the levels of NADPH oxidase-derived superoxide.
Further we examined the role Nlrp3 inflammasomes in visfatin-induced enhancement of podocyte monolayer permeability. There is substantial evidence that glomerular oxidative stress contributes to increases in epithelial monolayer permeability under different pathological conditions such as diabetes, nephritis, hypertension and hHcys [47, 48] . This increased cell permeability importantly participates in the development of glomerular injury and sclerosis [4, 49] . The present study demonstrated that visfatin-induced increase in the podocyte permeability was markedly attenuated by treatment of these cells with Asc siRNA transfection. Moreover, visfatin-induced decrease in the production of VEGF-A, as a glomerular permeability factor, was also reversed by prior treatment with Asc siRNA. These results suggest that visfatin may lead to reduce podocyte function and glomerular barrier integrity and that prior treatment with Asc siRNA prevents such pathological actions of visfatin and protects glomeruli from increased permeability.
Conclusion
In conclusion, the present study demonstrated that adipokine visfatin-induced inflammasome formation, activation and consequent podocyte injury. Therefore, targeting visfatin may be an important therapeutic strategy to prevent inflammasome activation and thereby protect glomeruli from obesity-induced podocyte injury and consequent glomerular injury.
